Royalty Pharma Valuation Multiples

Royalty Pharma Overview

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Founded

1996

HQ

Employees

100

Website

royaltypharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $3B

EV

$28B

Valuation Multiples

Multiples.vc

Start free trial

Royalty Pharma Financials

Royalty Pharma reported last 12-month revenue of $3B and EBITDA of $3B.

In the same LTM period, Royalty Pharma generated $3B in EBITDA and $3B in net income.

Royalty Pharma P&L

In the most recent fiscal year, Royalty Pharma reported revenue of $3B and EBITDA of $3B.

Royalty Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Royalty Pharma Stock Performance

Royalty Pharma has current market cap of $21B, and enterprise value of $28B.

Royalty Pharma's stock price is $48.31.

Royalty Pharma Valuation Multiples

Royalty Pharma trades at 8.7x EV/Revenue multiple, and 9.3x EV/EBITDA.

Royalty Pharma Financial Valuation Multiples

As of April 10, 2026, Royalty Pharma has market cap of $21B and EV of $28B.

Equity research analysts estimate Royalty Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Royalty Pharma has a P/E ratio of 7.5x.

Royalty Pharma Margins & Growth Rates

Royalty Pharma's revenue in the last 12 month grew by 2%.

Royalty Pharma's revenue per employee in the last FY averaged $32.5M, while opex per employee averaged $8.2M for the same period.

Royalty Pharma's rule of 40 is 133% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Royalty Pharma's rule of X is 188% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Royalty Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Royalty Pharma M&A Activity

Royalty Pharma acquired XXX companies to date.

Last acquisition by Royalty Pharma was on XXXXXXXX, XXXXX. Royalty Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Royalty Pharma Investment Activity

Royalty Pharma invested in XXX companies to date.

Royalty Pharma made its latest investment on XXXXXXXX, XXXXX. Royalty Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).